PDS Planning Inc Purchases 35 Shares of Medpace Holdings, Inc. $MEDP

PDS Planning Inc increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,421 shares of the company’s stock after acquiring an additional 35 shares during the quarter. PDS Planning Inc’s holdings in Medpace were worth $760,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MEDP. Mawer Investment Management Ltd. bought a new stake in Medpace during the 1st quarter worth about $212,131,000. Vulcan Value Partners LLC grew its position in shares of Medpace by 221.6% during the 1st quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company’s stock worth $99,159,000 after buying an additional 224,578 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in shares of Medpace by 675.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company’s stock worth $37,009,000 after buying an additional 105,807 shares during the last quarter. Invesco Ltd. raised its stake in shares of Medpace by 9.4% during the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock worth $361,596,000 after buying an additional 102,015 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in Medpace by 36.0% in the first quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock valued at $102,830,000 after buying an additional 89,347 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on MEDP. Rothschild Redb lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Weiss Ratings restated a “buy (b-)” rating on shares of Medpace in a research report on Wednesday. William Blair reaffirmed a “market perform” rating on shares of Medpace in a research note on Wednesday, July 23rd. UBS Group downgraded Medpace from a “neutral” rating to a “sell” rating and upped their price objective for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. Finally, Rothschild & Co Redburn cut Medpace from a “buy” rating to a “neutral” rating and raised their target price for the stock from $342.00 to $474.00 in a report on Wednesday, September 3rd. Three research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $422.27.

Medpace Stock Down 3.4%

Shares of MEDP stock opened at $501.22 on Friday. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $547.15. The firm has a fifty day moving average of $483.32 and a 200-day moving average of $374.92. The firm has a market capitalization of $14.08 billion, a price-to-earnings ratio of 37.27, a price-to-earnings-growth ratio of 3.15 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same quarter last year, the business posted $2.75 EPS. The firm’s revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Buying and Selling at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 3,000 shares of Medpace stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the transaction, the general counsel owned 10,343 shares of the company’s stock, valued at approximately $4,654,350. The trade was a 22.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 48,487 shares of the company’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the completion of the transaction, the chief executive officer owned 962,615 shares of the company’s stock, valued at $434,803,569.35. This trade represents a 4.80% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 161,266 shares of company stock worth $74,111,427 over the last three months. Company insiders own 20.30% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.